prikaz prve stranice dokumenta Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa
  Download
PDF 341.78 KB
master's thesis
Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa
Zagreb: University of Zagreb, School of Dental Medicine, 2020. urn:nbn:hr:127:292069
Penava, Nino
University of Zagreb
School of Dental Medicine
Department of Periodontology

Institutional repository: University of Zagreb School of Dental Medicine Repository

Cite this document

Penava, N. (2020). Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa (Master's thesis). Zagreb: University of Zagreb, School of Dental Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:127:292069

Penava, Nino. "Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa." Master's thesis, University of Zagreb, School of Dental Medicine, 2020. https://urn.nsk.hr/urn:nbn:hr:127:292069

Penava, Nino. "Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa." Master's thesis, University of Zagreb, School of Dental Medicine, 2020. https://urn.nsk.hr/urn:nbn:hr:127:292069

Penava, N. (2020). 'Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa', Master's thesis, University of Zagreb, School of Dental Medicine, accessed 11 July 2024, https://urn.nsk.hr/urn:nbn:hr:127:292069

Penava N. Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa [Master's thesis]. Zagreb: University of Zagreb, School of Dental Medicine; 2020 [cited 2024 July 11] Available at: https://urn.nsk.hr/urn:nbn:hr:127:292069

N. Penava, "Upotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa", Master's thesis, University of Zagreb, School of Dental Medicine, Zagreb, 2020. Available at: https://urn.nsk.hr/urn:nbn:hr:127:292069

Metadata
TitleUpotreba proteina caklinskog matriksa kod regenerativne terapije periimplantitisa
Title (english)Use of enamel matrix proteins in regenerative therapy of periimplantitis
AuthorNino Penava
MentorDomagoj Vražić (mentor)
Committee memberDomagoj Vražić (predsjednik povjerenstva)
Committee memberIvan Puhar (član povjerenstva)
Committee memberSamir Čimić (član povjerenstva)
GranterUniversity of Zagreb
School of Dental Medicine
(Department of Periodontology)
Zagreb
Defense date and country2020-07-07, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Dental Medicine
Periodontology
Abstract
Dentalni implantati sve su češći izbor prilikom nadoknade izgubljenih zuba, a samim tim raste i broj komplikacija. Najčešće biološke komplikacije su periimplantatni mukozitis i periimplantitis, biofilmom uzrokovane upale periimplantatnog mekog tkiva bez, odnosno s progresivnim gubitkom potporne kosti. Međutim, još ne postoji jedinstveni protokol u njegovom liječenju. U slučaju periimplantatnog mukozitisa najčešće je dovoljna nekirurška terapija, dok je za liječenje periimplantitisa metoda izbora kirurška terapija. Ovisno o konfiguraciji defekta odlučujemo se za resektivnu ili regenerativnu kirurgiju. U regenerativnoj kirurgiji najčešće se upotrebljavaju koštani nadomjesni materijali u kombinaciji s membranom. Iako se ova kombinacija pokazala uspješnom, sve se više istraživanja fokusira na bioaktivna sredstva koja bi mogla potaknuti regeneraciju. U skupinu bioaktivnih sredstava spadaju i proteini caklinskog matriksa koji sudjeluju u razvoju zuba tijekom mineralizacije cakline. Emdogain® komercijalno je dostupan preparat proteina caklinskog matriksa i sastoji se uglavnom od amelogenina otopljenog u kiselom propilen glikol alginatu. Proteini caklinskog matriksa najprije su se uspješno koristili u terapiji parodontnih infrakoštanih defekata i recesija, da bi se u novije vrijeme krenuli upotrebljavati i u terapiji periimplantatnih bolesti. Do sada objavljene studije uglavnom su niže razine dokaza, ali sugeriraju da bi proteini caklinskog matriksa mogli imati pozitivni učinak na regeneraciju kosti izgubljene periimplantitisom. Međutim, nedostaju veća randomizirana kontrolirana istraživanja koja bi ustvrdila njihovu točnu ulogu.
Abstract (english)
Dental implants are being used more and more to replace missing teeth, which in turn causes more complications. The most common biological complications are periimplantitis, periimplant mucositis, and biofilm mediated inflammation of the peri-implant soft tissues with/without the progressive loss of the supporting bone. However, we do not yet have a single treatment for peri-implant diseases. In case of peri-implant mucositis, nonsurgical therapy is often sufficient, but treating periimplantitis often requires surgery. Depending on defect configuration, we opt either for resective or regenerative surgery. In the latter, the most frequently used are bone grafts in combination with the membrane. Although this combination has proved to be successful, more and more research now focuses on bioactive agents that could stimulate regeneration. The bioactive agents include enamel matrix proteins that take part in tooth development during enamel mineralization. Emdogain® is a commercially available product of enamel matrix proteins that consists mostly of amelogenins diluted in acid propylene glycol alginate. Enamel matrix proteins were first successfully used in the treatment of recessions and infrabony periodontal defects. Today, they are applied to periimplantitis-affected sites as well. Studies published so far have mostly been positioned lower on the evidence-based medicine pyramid but they do suggest that enamel matrix proteins have a positive effect on bone regeneration. However, larger randomized controlled studies are needed to determine their exact role.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:127:292069
Study programmeTitle: dental medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica dentalne medicine (doktor/doktorica dentalne medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2021-01-20 11:30:32